Kyverna Therapeutics, Inc. (KYTX) vs Viemed Healthcare, Inc. (VMD)
A side-by-side comparison of Kyverna Therapeutics, Inc. and Viemed Healthcare, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYTX
Kyverna Therapeutics, Inc.
$6.16HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VMD
Viemed Healthcare, Inc.
$9.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — KYTX vs VMD
growth of $100 · dividends reinvested · last 3yKYTX -78.9% (-40.5%/yr)VMD +8.6% (+2.8%/yr)VMD compounded faster over this window
Log scale — wide-divergence pair
KYTX VMD
KYTX vs VMD: by the numbers
- •KYTX is the larger company ($374M vs $355M market cap).
- •VMD is profitable (4.81% net margin) while KYTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | KYTX | VMD |
|---|---|---|
| P/E ratio | N/A | 25.65 |
| Forward P/E | N/A | 22.57 |
| P/S ratio | N/A | 1.18 |
| P/B ratio | 2.26 | 2.47 |
| EV / EBITDA | N/A | 6.50 |
| FCF yield | N/A | 8.23% |
Profitability
| Metric | KYTX | VMD |
|---|---|---|
| Gross margin | 0.00% | 57.21% |
| Operating margin | 0.00% | 8.14% |
| Net margin | 0.00% | 4.81% |
| ROE | -92.20% | 10.07% |
| ROIC | -80.67% | 11.00% |
Growth (annualized)
| Metric | KYTX | VMD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.15% |
| EPS CAGR (5Y) | N/A | -15.07% |
| FCF CAGR (5Y) | N/A | -11.57% |
| Total return CAGR (5Y) | N/A | 10.93% |
Frequently asked
- Is KYTX or VMD more profitable?
- VMD runs the higher net margin — KYTX at 0.00% versus VMD at 4.81%.
Go deeper
Dig into the metrics
Viemed Healthcare P/E ratioKyverna Therapeutics ROEViemed Healthcare ROEKyverna Therapeutics operating marginViemed Healthcare operating marginKyverna Therapeutics revenue growthViemed Healthcare revenue growthKyverna Therapeutics free cash flowViemed Healthcare free cash flow
Kyverna Therapeutics & Viemed Healthcare appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.